| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919356 | Radiotherapy and Oncology | 2013 | 5 Pages |
Abstract
111In-cetuximab-F(ab')2 showed good tumor-to-background contrast on microSPECT imaging, allowing noninvasive assessment of EGFR expression in vivo, and possibly evaluation of treatment response to EGFR-inhibition.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Laura K. van Dijk, Bianca A.W. Hoeben, Hanneke Stegeman, Johannes H.A.M. Kaanders, Gerben M. Franssen, Otto C. Boerman, Johan Bussink,